HIV-1 infection also appears to alter the diagnosis, natural history, management, and outcome of T. pallidum infection [14] [15] [16] . In addition, HIV-1-infected adults with moreadvanced disease (i.e., those with CD4 + cell counts of !100 cells/mm 3 ) are at risk for illness caused by reactivation of various viral and protozoan pathogens, including cytomegalovirus (CMV; which causes retinitis, colitis, and encephalitis) and Toxoplasma gondii (which causes encephalitis).
Very limited data are available on the serologic prevalence of syphilis, HBV infection, HCV infection, T. gondii infection, and CMV infection among HIV-1-infected adults in subSaharan Africa, especially among HIV-1-infected individuals who are presenting for HAART initiation and, therefore, have evidence of advanced HIV-1 disease. The majority of existing literature is from West or East Africa and reports the serologic prevalence of these important disease pathogens among at-risk adult populations (i.e., women, blood donors, and prisoners) with unknown HIV-1-infection status [17] [18] [19] [20] [21] [22] [23] [24] [25] .
Methods. A total of 160 adult patients presenting for longitudinal care between May 2001 and January 2002 at the Infectious Disease Care Clinic for outpatient HIV care at Princess Marina Hospital in Gaborone, Botswana, were consecutively evaluated for the presence of syphilis, HBV infection, HCV infection, toxoplasmosis, and CMV infection. Baseline HIV-1 antibody levels, CD4
+ cell counts, and plasma HIV-1 RNA levels were also obtained. Not all adults were tested for HCV, T. gondii, and CMV antibodies, because once a consistent test result trend was found (i.e., у40 patients with test results negative for a particular pathogen), serologic testing for that pathogen was discontinued.
Nontreponemal Anti-toxoplasmal IgG antibody was found in 3 (6.5%) of 46 patients screened. None of the 46 patients screened had IgM antibody against T. gondii. CMV IgG antibody levels were positive in 41 (95.3%) of 43 patients. None of the 41 patients screened had anti-CMV IgM antibody.
Discussion. Evidence of prior syphilis infection was common among the first group of HIV-1-infected patients to initiate HAART in the Botswana National Antiretroviral Treatment program (found in 13.3% of patients). Recent Botswana syphilis prevalence data (from 2002) among adults with unknown HIV-1 status documented positivity rates of 1.7%-5.1% [26] among adults presenting with symptoms of sexually transmitted disease and attending family planning clinics; the rate was 6.6%-9.9% among pregnant women presenting for antenatal care as part of the 2003 National Sentinel Surveillance [27] . Both syphilis and HIV-1 infection share a common epidemiological mode of transmission; therefore, a higher prevalence of coinfection among patients with known advanced HIV-1 disease is not surprising. By performing both nontreponemal (RPR) and treponemal (TPHA) tests for all patients, we were able to document that ∼25% of positive RPR test results were not confirmed by the TPHA test. This suggests that ∼25% of patients receiving a diagnosis of syphilis using RPR as a screening test (and not confirmed by TPHA test) were treated unnecessarily. More data will need to be obtained via random TPHA confirmatory testing among patients with positive RPR test results to determine whether all patients with positive RPR test results should have the diagnosis confirmed by TPHA testing before receiving penicillin treatment, which can cause allergic drug reactions in susceptible hosts. The rate of asymptomatic patients with positive RPR test results does, however, provide public health justification for continued syphilis screening by routine RPR testing at entry to care.
HBV infection is also common among HIV-infected adults in Botswana; 58.2% of our initial cohort had antibody evidence of past infection, and 10.6% had circulating hepatitis B surface antigen, indicating chronic hepatitis. The 10% rate of chronic HBV infection, coupled with 40% of these carriers also being hepatitis B e antigen positive, suggests that the long-term complications of HBV infection may become a greater problem as many more persons receive HAART as part of Botswana's National Antiretroviral treatment program. Emtricitabine, lamuvidine, and tenofovir each have activity against both HIV-1 and HBV, and the discontinuation of these drugs may potentially cause significant hepatocellular damage, which results from a flare of HBV disease [28] . With very large numbers of adults now receiving lamuvidine-containing HAART in Botswana (and in the region as a whole), those persons who experience failure of first-line therapy and, therefore, require full HAART regimen switches will need to be monitored for clinical flares of HBV infection, especially during the first 6-8 weeks following discontinuation of therapy.
Fortunately, no patients were found to be infected with HCV, which is a significant cause of additive hepatotoxicity among HIV-1 subtype B-infected adults receiving HAART in developed nations. However, it will be important for Botswana to perform periodic surveillance to assure that its penetration into the population will not be missed, especially because the chronic hepatic complication rates associated with HCV infection are more significant. The absence of HCV infection most likely reflects the fact that the overwhelming majority of HIV-1 subtype C transmission in Botswana is through heterosexual contact, with little documented injection drug use.
Serological evidence of prior infection with T. gondii was quite uncommon in our population (infection rate, 6.5%), and clinical toxoplasmosis encephalitis is rare. On the other hand, prior CMV infection (indicated by anti-CMV IgG antibody and lack of IgM antibody) was almost universal, and CMV-related retinitis does occur. This high frequency of CMV infection is common for most developing nations, where infection is acquired early in childhood. Both of these organisms, upon reactivation, may cause serious CNS complications, although, at present, in the AIDS population in sub-Saharan Africa, cryptococcal meningitis, Mycobacterium tuberculosis, and AIDS dementia complex [29] [30] [31] are the most common causes of CNS disease.
This study potentially overestimates the prevalence of prior and/or active infection with these HIV-associated pathogens, because it was performed among a group of mostly symptomatic patients presenting for outpatient HIV care. Results may have been more reflective of population trends if this seroprevalence study was conducted among at-risk, asymptomatic patients. In addition, serological tests for CMV and toxoplasmosis may have poor clinical significance and predictive value among persons with very advanced HIV disease. In addition, not all adults had the full panel of serological tests performed as part of our screening approach. These serological tests were not done within the context of a clinical trial, and therefore, once у40 consecutively screened patients had test results negative for a particular serological test, for cost purposes, that particular test was no longer performed.
